Colorectal cancer, also known as bowel cancer, is a cancer formed by uncontrolled cell growth in the colon or rectum (parts of the large intestine), or in the appendix. Genetic analysis shows that colon and rectal tumours are genetically the same cancer. ...
In the past decades the incidence of colorectal cancer (CRC) in people under the age of 50 years has increased, which is referred to as early-onset CRC or young-onset CRC (YO-CRC). YO-CRC is expected to account for 11% of colon cancers and 23% of rectal
Figure 2. Literature Search Flow Diagram: Screening for Colorectal Cancer View LargeDownload KQ indicates key question. aArticles could be reviewed for more than 1 KQ. bReasons for exclusion: Relevance: Study aim not relevant. Design: Study did not use an included design. Setting: Study not co...
Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different immunological, stromal cell, and clinicopathological characteristics. Single-cell characterization of CMS subtype tumor microenvironments is required to elucidate mechanisms of tum
Eric M.MontminyMD, ...Jordan J.KarlitzMD, inMedical Clinics of North America, 2020 Colorectal cancer screeningis essential to detect and remove premalignant lesions to prevent the development of colorectal cancer. Multiple screening modalities are available, including colonoscopy and stool-based testin...
This 2021 Recommendation Statement from the US Preventive Services Task Force recommends screening for colorectal cancer in all adults aged 50 to 75 years
Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors. Since advanced colorectal cancer (CRC) has high mo
We acquired colorectal cancer mortality data from the Cause of Death Statistics in Korea from 2000 to 2020. We characterized the data into year of death, cancer-specific loci, and age group. We analyzed age-standardized mortality rates (ASMR) according to year of death, age group, and primary...
Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy. OncLive’s December Roundup of Key FDA Approvals in Oncology By Kristi Rosa December 31st 2024 Nivolumab Plus Ipilimumab Wins European Approval...
A significant proportion of colorectal cancer (CRC) patients develop peritoneal metastases (PM) in the course of their disease. PMs are associated with a poor quality of life, significant morbidity and dismal disease outcome. To improve care for this patient group, a better understanding of the ...